YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA approved YUTREPIA on May 23, 2025 Court denies United Therapeutics’ request for preliminary injunction and a temporary ...

MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its ...

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Lupin’s 18 µg capsules of tiotropium bromide inhalation powder, according to a manufacturer ...

6 out of 6 Patients Who Completed the 12-Week Treatment Have Chosen to Remain on TFF TAC by Proceeding to the Safety Extension Phase; 1 patient has been treated for over a year and 3 additional ...

Prior to prescribing Bronchitol, the Bronchitol Tolerance Test must be administered and performed under the supervision of a health care professional. Bronchitol ® (mannitol inhalation powder) is now ...

Please provide your email address to receive an email when new articles are posted on . The dry powder formulation of treprostinil studied in BREEZE is in development with a reusable breath-powered ...

—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in ...

Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil. The Food and Drug Administration (FDA) has accepted for Priority Review the New ...

MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...

FDA confirmed that the amendment to add PH-ILD to the YUTREPIA NDA was proper and that application otherwise meets the requirements for approval under the Federal Food, Drug, and Cosmetic Act Final ...